<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960763</url>
  </required_header>
  <id_info>
    <org_study_id>TRD-1511-33321</org_study_id>
    <secondary_id>201609085</secondary_id>
    <nct_id>NCT02960763</nct_id>
  </id_info>
  <brief_title>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to assess which antidepressants work the best in older
      adults who have treatment-resistant depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Older adult participants with treatment-resistant depression will be randomly assigned to a
      Step 1 medication strategy.

        -  Adding aripiprazole to current antidepressant medication

        -  Adding bupropion to current antidepressant medication

        -  Replacing current antidepressant medication with bupropion

      If depression is not relieved at the end of 10 weeks, participants will be randomly assigned
      to a Step 2 medication strategy:

        -  Adding lithium to current antidepressant medication

        -  Replacing current antidepressant medication with nortriptyline

      All medication strategies will be offered in collaboration with participants' own physicians
      with the the research team providing support and guidance.

      If depression has been relieved after Step 1 or 2, participants will enter the Continuation
      Phase to assess long term follow-up outcomes for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychological Well-Being</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Measured by NIH Toolbox Surveys: Positive Affect and General Life Satisfaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission from Depression</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Remission defined as Montgomery Asberg Depression Rating Scale score â‰¤10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Through study completion (20 weeks, 1 year and 10 weeks, or 1 year and 20 weeks)</time_frame>
    <description>Life threatening illness, hospitalization, or need of medical care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Falls</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Number of falls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fall-related Injuries</measure>
    <time_frame>10 weeks (end of Step, and, if applicable, end of Step 2)</time_frame>
    <description>Injuries or impairment resulting from falls</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Aripiprazole Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to Nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Aripiprazole Augmentation</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Bupropion Augmentation</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to bupropion</intervention_name>
    <description>Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.</description>
    <arm_group_label>Switch to Bupropion</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Augmentation</intervention_name>
    <description>Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.</description>
    <arm_group_label>Lithium Augmentation</arm_group_label>
    <other_name>Lithium carbonate</other_name>
    <other_name>Eskalith</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to nortriptyline</intervention_name>
    <description>Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml</description>
    <arm_group_label>Switch to Nortriptyline</arm_group_label>
    <other_name>Pamelor,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 60 and older

          -  Current Major Depressive Disorder (MDD)

          -  Failure to respond adequately to two or more antidepressant treatment trials of
             recommended dose and length (at least 12 weeks)

          -  Patient Health Questionnaire-9 (PHQ-9) score of 6 or higher

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Dementia

          -  Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective
             disorder, schizophreniform disorder, delusional disorder, or current psychotic
             symptoms

          -  High risk for suicide and unable to be managed safely in the clinical trial

          -  Contraindication to proposed study medications, as determined by study physician
             including history of intolerance or non-response to proposed medications.

          -  Non-correctable, clinically significant sensory impairment interfering with
             participation

          -  Unstable medical illness, including delirium, uncontrolled diabetes mellitus,
             hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that
             are not under medical management.

          -  Moderate to severe substance or alcohol use disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Lenard, MSW</last_name>
    <phone>314-474-5706</phone>
    <email>lenarde@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Schweiger, CCRC</last_name>
    <phone>314-362-3153</phone>
    <email>schweigj@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Late-Life Mood, Stress, and Wellness Research Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalie St. Cyr, MA</last_name>
      <phone>310-983-3375</phone>
      <email>nstcyr@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Helen Lavretsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Healthy Mind Lab</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Adult and Late Life Depression Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Brown, PhD</last_name>
      <phone>646-774-8666</phone>
      <email>pb2410@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Roose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Stack, RN, MSN, CNS</last_name>
      <phone>412-246-6006</phone>
      <email>StackJA@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jordan Karp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles F Reynolds III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J-1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Athina Perivolaris, RN, MN</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>32897</phone_ext>
      <email>athina.perivolaris@camh.ca</email>
    </contact>
    <investigator>
      <last_name>Benoit Mulsant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 7, 2016</lastchanged_date>
  <firstreceived_date>October 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Eric Lenze</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Comparative Effectiveness Research</keyword>
  <keyword>Pragmatic Clinical Trials</keyword>
  <keyword>Patient-Centered Outcomes Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A cleaned, complete, and de-identified copy of the final data set including administrative and technical metadata records will be made available through a Washington University in St. Louis (WUSTL) secure repository and registered at clinicaltrials.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
